COVID-19 doesn’t end in the acute phase! The Pneumocovid study estimates the clinical and biological risk factors and pulmonary impact of COVID-19 in the long term
Dr. Oriol Sibila, pneumologist, and leader of the section of Respiratory Cures of the Hospital clínic explains the project Pneumocovid at TV3. Among other topics, he answers questions on the influence of the air-conditioned in the contagion of the coronavirus, and he talks of the use of masks and the pulmonary sequels that the virus can leave.
Description of the Study:
- Title: Prognostic Factors and Pulmonary Impact in Patients Admitted with COVID-19. Long-term Follow-up.
- Principal Investigator: Oriol Sibila.
- Study Population: Over 230 patients.
- Center of Implementation: Hospital Clínic de Barcelona.
Objectives of the Study:
Principal Objective: Estimate the association between risk factors (clinical and biological) and the development of severe respiratory failure (defined by a PaO2 / FiO2 <200 mmHg) in patients hospitalized for infection with SARS-CoV-2 at Hospital Clínic.
Secondary Objective: To assess the impact of SARS-CoV-2 infection at the pulmonary level after hospital discharge for 12 months.
More about this Study:
Hospital Clínic de Barcelona: It is a public consortium formed by the Generalitat de Catalunya (CatSalut) and the University of Barcelona. It is organized in specialized Institutes, Diagnostic Centers, and Transversal Areas.
It is a highly specialized and technological public health center, recognized for its level of excellence and quality in the fields of care, research, innovation, and teaching.
The processes of healthcare innovation are encouraged in the search for new methodologies and constant changes are implemented to achieve increasingly efficient results for the benefit of people. There are different research groups such as the inflammation and repair in respiratory diseases in which Oriol Sibila participates.
The hospital has been a key element in the fight against the pandemic in Barcelona, taking in up to 90 COVID-19 patients a day during the months of march and april. The cohort of the Pneumocovid study can gather some of these COVID-19 patients to study their pulmonary sequelae.
